Dr. Amit R. Patel, MD
Urology (Urology Physician)
- Medicare participating
At a glance
- Medical school
- Ohio State University College of Medicine (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 756
Licensed in Illinois since 2010, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: Ohio State University College of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
IL license 036.125934 (first issued 2010; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Edward Hospital Naperville, IL
- Elmhurst Memorial Hospital Elmhurst, IL
- Advocate Good Samaritan Hospital Downers Grove, IL
Medical groups
- Dupage Medical Group LTD (1,322 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 756
- Services billed
- 11,820
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 3,780 | 12 |
| Psa (prostate specific antigen) measurement, total | 572 | 336 |
| Insertion of needle into vein for collection of blood sample | 539 | 344 |
| Established patient office or other outpatient visit, 30-39 minutes | 491 | 368 |
| Automated urinalysis test | 437 | 290 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 399 | 44 |
| Established patient office or other outpatient visit, 20-29 minutes | 233 | 209 |
| Ultrasound measurement of bladder capacity after voiding | 214 | 175 |
| Diagnostic exam of bladder and urethra using an endoscope | 106 | 85 |
| Injection of drug or substance under skin or into muscle | 80 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Hinsdale, IL | 606 |
| Finasteride Other prescribers in Hinsdale, IL | 495 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Hinsdale, IL | 191 |
| Alfuzosin Hcl Er (alfuzosin hcl) Other prescribers in Hinsdale, IL | 126 |
| Cephalexin Other prescribers in Hinsdale, IL | 117 |
| Orgovyx (relugolix) | 105 |
| Dutasteride Other prescribers in Hinsdale, IL | 99 |
| Tramadol Hcl Other prescribers in Hinsdale, IL | 93 |
| Methenamine Hippurate Other prescribers in Hinsdale, IL | 79 |
| Gemtesa (vibegron) Other prescribers in Hinsdale, IL | 62 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 30 companies reported 124 payments worth $31,298 in total to this clinician.
| Angiodynamics, Inc. | $8,946 |
|---|---|
| Intuitive Surgical, Inc. | $6,375 |
| Ethicon Inc. | $5,150 |
| Ferring Pharmaceuticals Inc. | $4,617 |
| AstraZeneca Pharmaceuticals LP | $1,688 |
| Janssen Scientific Affairs, LLC | $1,434 |
| Histosonics, Inc. | $1,002 |
| Janssen Biotech, Inc. | $317 |
| Consulting Fee | $14,588 |
|---|---|
| Travel and Lodging | $4,749 |
| Compensation for services other than consulting (speaking, faculty) | $4,275 |
| Education | $4,026 |
| Food and Beverage | $3,567 |
| Entertainment | $93.33 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Angiodynamics, Inc. Feb 14, 2025 | Consulting Fee NANOKNIFE · OS | $6,600 |
| Ferring Pharmaceuticals Inc. Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $4,275 |
| Intuitive Surgical, Inc. Mar 26, 2025 | Education Da Vinci Surgical System · SURGERY | $4,000 |
| Angiodynamics, Inc. Feb 14, 2025 | Travel and Lodging NANOKNIFE · OS · travel to CHICAGO, IL | $1,898 |
| AstraZeneca Pharmaceuticals LP Dec 19, 2025 | Consulting Fee IMFINZI · Oncology Company’s descriptionResearch Related Service | $1,688 |
| Janssen Scientific Affairs, LLC Sep 3, 2025 | Consulting Fee | $1,150 |
| Ethicon Inc. Apr 11, 2025 | Consulting Fee | $800 |
| Histosonics, Inc. Jun 18, 2025 | Travel and Lodging travel to Plymouth, MN | $777 |
| Ethicon Inc. May 15, 2025 | Consulting Fee | $600 |
| Ethicon Inc. Jun 9, 2025 | Consulting Fee | $600 |
All 26 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 19, 2025 | Consulting Fee IMFINZI · Oncology Company’s descriptionResearch Related Service | $1,688 |
| Ethicon Inc. Nov 13, 2025 | Consulting Fee | $150 |
| Ferring Pharmaceuticals Inc. Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $4,275 |
| Ethicon Inc. Oct 13, 2025 | Consulting Fee | $500 |
| Edap Technomed Inc Oct 8, 2025 | Entertainment FOCAL ONE · Prostate Cancer | $93.33 |
| Ethicon Inc. Sep 10, 2025 | Consulting Fee | $250 |
| Janssen Scientific Affairs, LLC Sep 3, 2025 | Consulting Fee | $1,150 |
| Ethicon Inc. Aug 11, 2025 | Consulting Fee | $250 |
| Merck Sharp & Dohme LLC Jul 31, 2025 | Education LYNPARZA · ONCOLOGY · in-kind | $25.70 |
| Ethicon Inc. Jul 14, 2025 | Consulting Fee | $550 |
| Histosonics, Inc. Jun 18, 2025 | Travel and Lodging travel to Plymouth, MN | $777 |
| Ethicon Inc. Jun 9, 2025 | Consulting Fee | $600 |
| Ethicon Inc. May 15, 2025 | Consulting Fee | $600 |
| Ethicon Inc. Apr 11, 2025 | Consulting Fee | $800 |
| Intuitive Surgical, Inc. Mar 28, 2025 | Travel and Lodging Da Vinci Surgical System · SURGERY · travel to WILKES-BARRE, PA · in-kind | $257 |
| Intuitive Surgical, Inc. Mar 26, 2025 | Education Da Vinci Surgical System · SURGERY | $4,000 |
| Intuitive Surgical, Inc. Mar 24, 2025 | Travel and Lodging Da Vinci Surgical System · SURGERY · travel to WILKES-BARRE, PA · in-kind | $576 |
| Intuitive Surgical, Inc. Mar 24, 2025 | Travel and Lodging Da Vinci Surgical System · SURGERY · travel to WILKES-BARRE, PA · in-kind | $504 |
| Intuitive Surgical, Inc. Mar 22, 2025 | Travel and Lodging Da Vinci Surgical System · SURGERY · travel to SCRANTON, PA · in-kind | $146 |
| Ethicon Inc. Mar 7, 2025 | Consulting Fee | $600 |
| Intuitive Surgical, Inc. Mar 6, 2025 | Travel and Lodging Da Vinci Surgical System · SURGERY · travel to WILKES-BARRE, PA · in-kind | $563 |
| Intuitive Surgical, Inc. Mar 6, 2025 | Travel and Lodging Da Vinci Surgical System · SURGERY · travel to WILKES-BARRE, PA · in-kind | $30.00 |
| Angiodynamics, Inc. Feb 14, 2025 | Consulting Fee NANOKNIFE · OS | $6,600 |
| Angiodynamics, Inc. Feb 14, 2025 | Travel and Lodging NANOKNIFE · OS · travel to CHICAGO, IL | $1,898 |
| Ethicon Inc. Feb 10, 2025 | Consulting Fee | $300 |
| Ethicon Inc. Jan 16, 2025 | Consulting Fee | $550 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $189,628 in research payments for these studies, mostly to the institutions running them.
- A phase 3 randomized openlabel study of PF06821497 mevrometostat in combination with enzalutamide compared with enzalutamide or docetaxel in participants with metastatic castration resistant prostate cancer previously…
Pfizer Inc. - A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
Sumitomo Pharma America, Inc. · Completed · NCT05467176 - A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)
Janssen Research & Development, LLC - A phase 3 randomized double blind placebo controlled study of PF06821497 mevrometostat with enzalutamide in metastatic castration resistant prostate cancer MEVPRO2
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.